Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Galera Therapeutics, Inc. (GRTX)

1.41   -0.04 (-2.76%) 08-18 07:41
Open: 1.45 Pre. Close: 1.45
High: 1.46 Low: 1.41
Volume: 10,476 Market Cap: 38(M)
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical trial for the treatment of radiotherapy induced severe oral mucositis in patients with head and neck cancer (HNC); in Phase IIa clinical trial for the treatment of radiotherapy-induced esophagitis in patients with lung cancer; and in Phase IIa clinical trial for patients with HNC undergoing standard-of-care radiotherapy. It is also involved in developing GC4711, a superoxide dismutase mimetic product candidate, which is in Phase I/II clinical trial in combination with stereotactic body radiation therapy (SBRT) in patients with non-small cell lung cancer and locally advanced pancreatic cancer. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.46 - 1.47 1.47 - 1.48
Low: 1.39 - 1.4 1.4 - 1.41
Close: 1.4 - 1.41 1.41 - 1.42

Technical analysis

as of: 2022-08-17 4:23:49 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 1.75     One year: 2.04
Support: Support1: 1.26    Support2: 1.12
Resistance: Resistance1: 1.5    Resistance2: 1.75
Pivot: 1.26
Moving Average: MA(5): 1.41     MA(20): 1.24
MA(100): 1.56     MA(250): 2.89
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 83.8     %D(3): 86.8
RSI: RSI(14): 61.4
52-week: High: 9.31  Low: 1.12
Average Vol(K): 3-Month: 85 (K)  10-Days: 73 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ GRTX ] has closed below upper band by 17.6%. Bollinger Bands are 1.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 12 Aug 2022
Insiders at Galera Therapeutics, Inc. (NASDAQ:GRTX) recouped some losses this week after buying this year, still down US$28k - Simply Wall St

Sun, 29 May 2022
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology - MyChesCo

Mon, 16 May 2022
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates - GlobeNewswire

Mon, 02 May 2022
Galera's avasopasem reduces esophagitis in patients receiving chemoradiotherapy - Seeking Alpha

Wed, 27 Apr 2022
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting - Yahoo Finance

Tue, 19 Oct 2021
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis - Yahoo Finance

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 27 (M)
Shares Float 18 (M)
% Held by Insiders 5.5 (%)
% Held by Institutions 45.3 (%)
Shares Short 488 (K)
Shares Short P.Month 557 (K)

Stock Financials

EPS -2.95
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -2.64
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -61
Return on Equity (ttm) 0
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.55
Qtrly Earnings Growth 0
Operating Cash Flow -64 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -0.48
PEG Ratio -0.1
Price to Book value -0.54
Price to Sales 0
Price to Cash Flow -0.6

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.